Pharmaceutics (Dec 2015)

Montelukast Disposition: No Indication of Transporter-Mediated Uptake in OATP2B1 and OATP1B1 Expressing HEK293 Cells

  • Marie Brännström,
  • Pär Nordell,
  • Britta Bonn,
  • Andrew M. Davis,
  • Anna-Pia Palmgren,
  • Constanze Hilgendorf,
  • Katarina Rubin,
  • Ken Grime

DOI
https://doi.org/10.3390/pharmaceutics7040554
Journal volume & issue
Vol. 7, no. 4
pp. 554 – 564

Abstract

Read online

Clinical studies with montelukast show variability in effect and polymorphic OATP2B1-dependent absorption has previously been implicated as a possible cause. This claim has been challenged with conflicting data and here we used OATP2B1-transfected HEK293 cells to clarify the mechanisms involved. For montelukast, no significant difference in cell uptake between HEK-OATP2B1 and empty vector cell lines was observed at pH 6.5 or pH 7.4, and no concentration-dependent uptake was detected. Montelukast is a carboxylic acid, a relatively potent inhibitor of OATP1B1, OATP1B3, and OATP2B1, and has previously been postulated to be actively transported into human hepatocytes. Using OATP1B1-transfected HEK293 cells and primary human hepatocytes in the presence of OATP inhibitors we demonstrate for the first time that active OATP-dependent transport is unlikely to play a significant role in the human disposition of montelukast.

Keywords